Oxford-AstraZeneca vaccine recommended for adults of all ages, WHO says

Geneva: Oxford-AstraZeneca’s COVID-19 vaccine is safe and effective and should be deployed widely, including in countries where the South African variant of the coronavirus may reduce its efficacy, a World Health Organisation panel says.

In interim recommendations on the shot, the Strategic Advisory Group of Experts on Immunisation (SAGE) panel said on Thursday AEDT that the vaccine should be given in two doses with an interval of eight to 12 weeks, and should also be used in people aged 65 and older.

“There is no reason not to recommend [the Oxford-AstraZeneca vaccine’s] use”, the scientists said.Credit:AP

Even in countries such as South Africa, where questions have been raised about the vaccine’s efficacy against a newly emerged variant of the SARS-CoV-2 coronavirus, “there is no reason not to recommend its use”, SAGE’s chair, Alejandro Cravioto, told a briefing.

“We have made a recommendation that even if there is a reduction in the possibility of this vaccine having a full impact in its protection capacity, especially against severe disease, there is no reason not to recommend its use even in countries that have circulation of the variant,” he said.

South Africa this week paused part of its rollout of the AstraZeneca vaccine after data from a small trial showed it did not protect against mild to moderate illness from the 501Y.V2 variant of the coronavirus now dominant in the country.

The WHO said those preliminary findings “highlight the urgent need for a co-ordinated approach for surveillance and evaluation of variants” and their impact on vaccine efficacy.

“The WHO will continue to monitor the situation (and) as new data become available, recommendations will be updated accordingly,” it said.

The Oxford-AstraZeneca vaccine is in the final stages of review for a WHO emergency-use listing and could receive approval by mid-February, the United Nations health agency said.

Asked why the WHO was pushing ahead with recommendations on using the vaccine even before much-anticipated data from a large US clinical trial of the shot, Cravioto said the US data was “not expected until into March”.

“We have thousands of people dying from the infection, in many countries of the world, daily,” he said.

“Anything we can do to use a product that might reduce that is totally justified, even if the information… is not (as) complete as we like.”


Get our Coronavirus Update newsletter

Stay across the news you need to know related to the pandemic. Sent Monday and Thursday. Sign up here.

Most Viewed in World

Source: Read Full Article